Immuno-oncology
Conference Coverage
CAR T-cell benefit in lenalidomide-refractory myeloma
“Early CAR Ts demonstrating efficacy and safety and prior lines of treatment impact survival from CAR T in myeloma. Can this also be true for...
Conference Coverage
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer
A novel therapy has a favorable safety profile, and more like it may be on the way.
Conference Coverage
Up-front pembro plus chemo boost survival in cervical cancer
Adding immunotherapy resulted in a 40% reduction in risk of death, compared with chemotherapy alone, for women with advanced cervical cancers...
Conference Coverage
‘Huge step forward’ in advanced ovarian cancer
A preplanned interim analysis revealed that the addition of durvalumab and olaparib was associated with a 37% improvement of PFS, compared with...
Conference Coverage
SCLC: Bispecific antibody shows phase 1 promise
The antibody targets delta-like ligand 3, which is one of few surface markers for small cell lung cancer.
Conference Coverage
‘Exciting’ results for cancer vaccine plus pembro in melanoma
A new randomized study is the first to demonstrate improvement in recurrence-free survival in melanoma with an individualized neoantigen vaccine...
From the Journals
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
Conference Coverage
Study gives new insight into timing of combo treatment in metastatic NSCLC
Best outcomes came when immunotherapy followed radiotherapy by 1-12 months.
From the Journals
Thoracic cancer approvals differ at FDA, EMA
The EMA had fewer approvals and took longer to make decisions.
Latest News
Adverse events linked to better survival with ICIs in melanoma
“We feel these findings will help clinicians in discussions with patients and in clinical decision-making after adverse events develop,” one of...
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.